Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2015-05-10 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 3B - Exercise of employee options 13 pages 138.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, terms, issue price, purpose, and application for quotation on the ASX (Australian Securities Exchange). It references ASX rules and compliance, and includes sections typical of a new share issue announcement such as security holder approvals, quotation agreements, and distribution schedules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a formal announcement related to capital raising and issuance of new shares or options. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is not a mere announcement of a report but the actual issuance announcement.
2015-05-10 English
Pharmaxis Signs Second Agreement with Chiesi 2 pages 127.5KB
Capital/Financing Update Classification · 95% confidence The document is a media release dated 8 May 2015 announcing a new exclusive distribution and supply agreement between Pharmaxis and Chiesi for the commercialization of Bronchitol in certain European countries. It contains no financial statements, no regulatory form references, no voting results, no management changes, no earnings data, and no detailed financial or operational analysis. It is a corporate announcement about a commercial agreement and partnership, typical of a Capital/Financing Update or business development announcement. Given the content and nature, the best fitting category is Capital/Financing Update (CAP). The document length is about 4917 characters, which is consistent with a press release rather than a full report or regulatory filing. Confidence is high due to clear content type and absence of other report indicators.
2015-05-07 English
Appendix 3B - Exercise of employee options 13 pages 138.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, exercise prices, terms of options, and application for quotation of additional securities on the ASX (Australian Securities Exchange). It references specific ASX rules and compliance requirements related to new share issues and securities quotation. The content is focused on the announcement and details of a new share issue and related securities, not a financial report or earnings release. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues or capital changes.
2015-04-23 English
Shareholder Update - March Quarter 2015 5 pages 139.7KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed shareholder update for the March quarter 2015 from Pharmaxis Ltd. It includes a CEO letter discussing business progress, clinical trial updates, partnership agreements, and detailed financial statements for the three and nine months ended 31 March 2015. The presence of comprehensive financial data, including income statements, expenses, net loss, and cash flow commentary, indicates this is a substantive quarterly financial report rather than a brief announcement or presentation. The document length (12,455 characters) and the inclusion of financial tables and management commentary align with the characteristics of an Interim / Quarterly Report (IR). There is no indication that this is an earnings release (which would be shorter and less detailed), nor is it an annual report or audit report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2015
2015-04-16 English
Appendix 4C - quarterly cash flow 5 pages 103.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The report covers a quarterly period ending 31 March 2015. The content is substantive with actual financial figures and analysis, not merely an announcement or certification. Appendix 4C is a recognized quarterly report format used in Australian stock exchange filings to provide quarterly financial updates. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2015
2015-04-16 English
Interim Results of Phase 1 Clinical Trial for PXS4728A 2 pages 123.5KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 7 April 2015 from Pharmaxis Ltd announcing positive interim results from a Phase 1 clinical trial for a drug candidate (PXS4728A). It discusses clinical trial stages, dosage, safety, and future presentations of results. There is no financial data, no regulatory filing references, no shareholder or board information, and no mention of financial results or reports. The document is a press release about clinical trial progress, which does not fit into financial or regulatory report categories. Given the content and nature, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2015-04-06 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.